Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
CONFIRMED88% CONFIDENCEThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]
Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.
$2.9B
1.00